Sitemap > Breaking Research > Immunology & Inflammatory Diseases
Displaying 201 - 250 of 5698 results
- Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis.
- Inhibition of scratching behaviour caused by contact dermatitis in histidine decarboxylase gene knockout mice.
- Oral administration of a T cell epitope inhibits symptoms and reactions of allergic rhinitis in Japanese cedar pollen allergen-sensitized mice.
- A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo.
- A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis.
- Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models.
- Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators.
- Novel ligands for the chemokine receptor-3 (CCR3): a receptor-modeling study based on 5D-QSAR.
- Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis.
- Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis.
- Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice.
- An experimental model of autoimmune pancreatitis in the rat.
- The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis.
- A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice.
- Matricellular homologs in the foreign body response: hevin suppresses inflammation, but hevin and SPARC together diminish angiogenesis.
- Therapeutic targeting of endothelial ligands for L-selectin (PNAd) in a sheep model of asthma.
- Inhibition of eosinophil survival by a selective inhibitor of phosphodiesterase 4 via the induction of apoptosis.
- Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.
- Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens.
- Synthesis and SAR of diazepine and thiazepine TACE and MMP inhibitors.
- Nonpeptide alpha(v)beta3 antagonists: identification of potent, chain-shortened 7-oxo RGD mimetics.
- Discovery and SAR studies of a novel series of noncovalent cathepsin S inhibitors.
- Isosteric ramatroban analogs: selective and potent CRTH-2 antagonists.
- A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.
- Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice.
- Induction of T-cell apoptosis in rats by genetically engineered glioma cells expressing granulocyte-macrophage colony-stimulating factor and B7.1.
- Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution.
- Biodistribution and metabolism of immunostimulatory oligodeoxynucleotide CPG 7909 in mouse and rat tissues following subcutaneous administration.
- Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer.
- Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity.
- The chemokine receptor D6 limits the inflammatory response in vivo.
- Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.
- Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy.
- PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
- Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse.
- Association between a variation in the phosphodiesterase 4D gene and bone mineral density.
- Novel TLR4-antagonizing peptides inhibit LPS-induced release of inflammatory mediators by monocytes.
- Engineering of vault nanocapsules with enzymatic and fluorescent properties.
- Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination.
- Circumventing multidrug resistance in cancer by beta-galactoside binding protein, an antiproliferative cytokine.
- Monoclonal anti-idiotype antibody 6G6.C4 fused to GM-CSF is capable of breaking tolerance to carcinoembryonic antigen (CEA) in CEA-transgenic mice.
- Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial.
- A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity.
- Phase I study of TNFalpha AutoVaccIne in patients with metastatic cancer.
- LL-37 enhances adaptive antitumor immune response in a murine model when genetically fused with M-CSFR (J6-1) DNA vaccine.
- Design, synthesis, and biological evaluation of N-acetyl-2-carboxybenzenesulfonamides: a novel class of cyclooxygenase-2 (COX-2) inhibitors.
- Inhibitory activity of a ceramide library on interleukin-4 production from activated T cells.
- A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.
- Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.
- Effect of the macrolide antibacterial drug, tylosin, on TNBS-induced colitis in the rat.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | 100 | 101 | 102 | 103 | 104 | 105 | 106 | 107 | 108 | 109 | 110 | 111 | 112 | 113 | 114 Next >